Soligenix announced that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behcet’s Disease has received “Fast Track” designation from the U.S. FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNGX:
- Biotech Alert: Searches spiking for these stocks today
- Soligenix reports top-line results of Phase 2a study of SGX302 in psoriasis
- Soligenix anounces publication showing efficacy of ebolavirus and MARV vaccine
- Soligenix rallies after Chief Scientific Officer authors paper in ScienceDirect
- Soligenix jumps170% after FDA clears IND application for dusquetide in Behcet’s
